Dexamethasone in Traumatic Brain Injury

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAssiut University

About this trial

In this study, our aim is to investigate the role of Dexamethasone for modulating the inflammation in patients with traumatic brain injury (TBI).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Isolated traumatic brain injury patients (mild or moderate cases)

GCS > 8

non penetrating TBI in 8 hours onset

Age ≥ 18 years

Disqualifiers

Patient in cardiac arrest

Patients with coagulopathies

All diabetic patients

Renal failure patients

Trial design

Design model

Parallel

Treatments tested in this trial

  • Saline

    Other intervention

    Giving saline 0.9% (loading dose of 5 ml of saline 0.9%, followed by a 5 ml of maintenance saline 0.9% dose every 6 hours for 48 h).

  • Dexamethasone

    Drug

    Giving Dexamethasone (loading dose of 10 mg dilutedin 5 ml saline, followed by a 8 mg in 5 ml saline of maintenance dose every 6 hours for 48 h).

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Group CPlacebo comparator 1 intervention
Group B: Group DExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Percentage of patients with decreased the inflammatory response

Percentage of patients with decreased the inflammatory response, as assessed by NLR measurements

Time frame
48 hours post-interventional (either placebo or Dexamethasone)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.